高尿酸血症性肾损害小鼠模型 z-bo 2020-12-28 331

　　Objective: To establish a reasonable and stable mouse model of hyperuricemia kidney damage, and provide a pathological model for screening and researching drugs for the treatment of hyperuricemia nephropathy.

　　Method: Use potassium oxazinate, hypoxanthine, adenine, ethambutol and yeast extract 5 kinds of modeling agents for single use, combination of two drugs or combination of three drugs, observe different modeling time, modeling dosage and modeling Changes in serum uric acid, urea nitrogen, and creatinine levels in the mouse hyperuricemia kidney damage model established by the method, liver xanthine oxidase (XOD) and adenosine deaminase (ADA) activities. Pathological changes of the kidneys and changes in body weight of each group.

　　Results: Compared with the normal group, the serum uric acid level and urea nitrogen of mice were significantly increased in the single-time model of hypoxanthine and potassium oxazinate (P<0.01), renal tubular casts and renal medulla were seen in the renal cortex. Salt crystals can be seen; the 7d group of mice with hypoxanthine, ethambutol and potassium oxazine combined with three drugs, serum uric acid levels and urea nitrogen were significantly increased (P<0.01), and liver XOD activity was significantly reduced (P<0.05) , The eosinophilic insoluble protein can be seen in the renal proximal convoluted tubules; the 14d group of yeast extract and potassium oxonate and the 14d group of yeast extract, adenine and potassium oxonate, compared with the normal group, the serum uric acid of mice was Urea nitrogen and creatinine values were significantly increased (P<0.01). In the combined group of yeast cream and potassium oxazinate, renal tubular epithelial cells could be shed, and eosinophilic insoluble protein could be seen in the renal proximal convolute tubules, yeast cream, adenine and oxygen Salt crystals can be seen in the kidney medulla of mice in the potassium oxazinate combined group. The weight gain of the mice in the combined yeast extract and potassium oxazinate group is faster than that in the yeast paste, adenine and potassium oxazinate combined group. There is a difference between the two groups Significant (P<0.05).

　　Conclusion: Compared with other modeling methods, the hyperuricemia renal damage mouse model established by the combination of yeast extract and potassium oxazinate is more stable and has no significant effect on the weight of the mice. At the same time, this modeling method is more clinically in line Therefore, it is more appropriate to establish a mouse model of hyperuricemia renal damage with yeast extract and potassium oxazinate for 14 days.